Click here for slides on this topic


End-stage renal disease (ESRD)

The most severe, fully developed phase of renal disease, in which the kidneys have lost so much function that dialysis or kidney transplantation is needed for patient survival.


The following content matched the glossary term: End-stage renal disease (ESRD)

Changes in diabetes-related complications in the United States, 1990–2010

Top

Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med. 2014;370:1514-1523.

American Diabetes Association (ADA)/American Geriatrics Society (AGS) Guidelines 2012

Top

Diabetes management guidelines for older adults from the American Diabetes Association (ADA)/American Geriatrics Society (AGS) 

Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis

Top

Coca SG, Ismail-Beigi F, Haq N, Krumholz HM, Parikh CR. Role of intensive glucose control in development of renal end points in type 2 diabetes: systematic review and meta-analysis. Arch Intern Med. 2012;172(10:761-769

Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the ACCORD experience

Top

Bonds DE, Craven TE, Buse J, Crouse JR, Cuddihy R, Elam M, Ginsberg HN, Kirchner K, Marcovina S, Mychaleckyj JC, O'Connor PJ, Sperl-Hillen JA. Fenofibrate associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience. Diabetologia. 2012 Mar 27. Epub ahead of print. Fenofibrate has been noted to cause an elevation in serum creatinine in some individuals.

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment

Top

Nowicki M, Rychlik I, Haller H, et al. Int J Clin Pract . Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. 2011;65(12):1230-1239. Nowicki and colleagues examined the effects of the dipeptidyl peptidase-4 (DPP-4) inhibitor, saxagliptin, among patients with inadequately controlled type 2 diabetes and renal impairment in a 52-week study.

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD study

Top

Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; on behalf of the FIELD Study Investigators. Benefits and safety of long term fenofibrate therapy in people with type 2 diabetes and renal impairment the FIELD study. Diabetes Care. 2012 Feb;35(2):218-225. OBJECTIVE Diabetic patients with moderate renal impairment are at particular cardiovascular risk.

Nontraditional markers of glycemia: associations with microvascular conditions(2)

Top

Selvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW. Nontraditional markers of glycemia: associations with microvascular conditions. Diabetes Care. 2011;34(4):960-7. To compare the associations of nontraditional (fructosamine, glycated albumin, 1,5-anhydroglucitol [1,5-AG]) and standard (fasting glucose, HbA(1c)) glycemic markers with common microvascular conditions associated with diabetes mellitus.

Nontraditional markers of glycemia: associations with microvascular conditions

Top

Nontraditional markers of glycemia associations with microvascular conditionsSelvin E, Francis LM, Ballantyne CM, Hoogeveen RC, Coresh J, Brancati FL, Steffes MW.Diabetes Care. 2011 Feb 18. Epub ahead of print   To compare the associations of nontraditional (fructosamine, glycated albumin, 1,5-anhydroglucitol [1,5-AG]) and standard (fasting glucose, glycated HbA(1c)) glycemic markers with common microvascular conditions associated with diabetes mellitus.

Risk of type 2 diabetes among individuals with high and low glomerular filtration rates

Top

Lorenzo C, Nath SD, Hanley AJ, Abboud HE, Gelfond JA, Haffner SM. Risk of type 2 diabetes among individuals with high and low glomerular filtration rates. Diabetologia. 2009;52(7):1290-1297. Metabolic abnormalities frequently develop prior to the diagnosis of type 2 diabetes and chronic kidney disease. However, it is not known whether GFR predicts the onset of type 2 diabetes.

1 2 3 Next 

Slide Library Results

Search Results for: End-stage renal disease (ESRD) Slides Found: 4
Rates of End-Stage Renal Disease in Diabetes Four Ethnic Groups
Saxagliptin for Treatment of Subjects with Type 2 Diabetes and Renal Impairment: Additional Results
DPP-4 Inhibitors: Dosage Adjustment by Degree of Renal Impairment
GLP-1 Receptor Agonists: Dosage Adjustment by Degree of Renal Impairment